Search research articles
Contact Us
Filters
Showing results (421-430 of 703) with videos related to
Page
of 71
Sort By:
BMJ Open
|
March 1, 2020
Identifying challenges to implementation of clinical practice guidelines for sentinel lymph node biopsy in patients with melanoma in Australia: protocol paper for a mixed methods study
Frances Rapport, Andrea L Smith, Anne E Cust, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
December 8, 2022
Clinical Features Associated with Outcomes and Biomarker Analysis of Dabrafenib plus Trametinib Treatment in Patients with BRAF-Mutant Melanoma Brain Metastases
James S Wilmott, Hussein Tawbi, Johnathan A Engh, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
April 3, 2019
Reply to E. Hindié and K.R. Hess
Georgina V Long, Reinhard Dummer, Dirk Schadendorf, et al.
European Journal of Cancer (Oxford, England : 1990)
|
September 27, 2021
Long-term outcomes in patients with advanced melanoma who had initial stable disease with pembrolizumab in KEYNOTE-001 and KEYNOTE-006
Omid Hamid, Caroline Robert, Adil Daud, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
December 13, 2024
Three-Year Overall Survival With Nivolumab Plus Relatlimab in Advanced Melanoma From RELATIVITY-047
Hussein A Tawbi, F Stephen Hodi, Evan J Lipson, et al.
Science Signaling
|
August 20, 2015
The transcription cofactor c-JUN mediates phenotype switching and BRAF inhibitor resistance in melanoma
Rachel Ramsdale, Robert N Jorissen, Frederic Z Li, et al.
Nature Medicine
|
October 6, 2020
Combined PD-1, BRAF and MEK inhibition in advanced BRAF-mutant melanoma: safety run-in and biomarker cohorts of COMBI-i
Reinhard Dummer, Celeste Lebbé, Victoria Atkinson, et al.
The Lancet. Oncology
|
July 27, 2019
Pembrolizumab versus ipilimumab in advanced melanoma (KEYNOTE-006): post-hoc 5-year results from an open-label, multicentre, randomised, controlled, phase 3 study
Caroline Robert, Antoni Ribas, Jacob Schachter, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
August 30, 2025
Randomized, Double-Blind, Phase III LEAP-003 Study of First-Line Lenvatinib Plus Pembrolizumab Versus Placebo Plus Pembrolizumab for Unresectable or Metastatic Melanoma
A Arance, M-A Berciano-Guerrero, J Guo, et al.
The New England Journal of Medicine
|
September 12, 2017
Adjuvant Dabrafenib plus Trametinib in Stage III BRAF-Mutated Melanoma
Georgina V Long, Axel Hauschild, Mario Santinami, et al.
Page
of 71
Search research articles
Search
Showing results (421-430 of 703) with videos related to
Sort By:
Page
of 71
BMJ Open
|
March 1, 2020
Identifying challenges to implementation of clinical practice guidelines for sentinel lymph node biopsy in patients with melanoma in Australia: protocol paper for a mixed methods study
Frances Rapport, Andrea L Smith, Anne E Cust, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
December 8, 2022
Clinical Features Associated with Outcomes and Biomarker Analysis of Dabrafenib plus Trametinib Treatment in Patients with BRAF-Mutant Melanoma Brain Metastases
James S Wilmott, Hussein Tawbi, Johnathan A Engh, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
April 3, 2019
Reply to E. Hindié and K.R. Hess
Georgina V Long, Reinhard Dummer, Dirk Schadendorf, et al.
European Journal of Cancer (Oxford, England : 1990)
|
September 27, 2021
Long-term outcomes in patients with advanced melanoma who had initial stable disease with pembrolizumab in KEYNOTE-001 and KEYNOTE-006
Omid Hamid, Caroline Robert, Adil Daud, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
December 13, 2024
Three-Year Overall Survival With Nivolumab Plus Relatlimab in Advanced Melanoma From RELATIVITY-047
Hussein A Tawbi, F Stephen Hodi, Evan J Lipson, et al.
Science Signaling
|
August 20, 2015
The transcription cofactor c-JUN mediates phenotype switching and BRAF inhibitor resistance in melanoma
Rachel Ramsdale, Robert N Jorissen, Frederic Z Li, et al.
Nature Medicine
|
October 6, 2020
Combined PD-1, BRAF and MEK inhibition in advanced BRAF-mutant melanoma: safety run-in and biomarker cohorts of COMBI-i
Reinhard Dummer, Celeste Lebbé, Victoria Atkinson, et al.
The Lancet. Oncology
|
July 27, 2019
Pembrolizumab versus ipilimumab in advanced melanoma (KEYNOTE-006): post-hoc 5-year results from an open-label, multicentre, randomised, controlled, phase 3 study
Caroline Robert, Antoni Ribas, Jacob Schachter, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
August 30, 2025
Randomized, Double-Blind, Phase III LEAP-003 Study of First-Line Lenvatinib Plus Pembrolizumab Versus Placebo Plus Pembrolizumab for Unresectable or Metastatic Melanoma
A Arance, M-A Berciano-Guerrero, J Guo, et al.
The New England Journal of Medicine
|
September 12, 2017
Adjuvant Dabrafenib plus Trametinib in Stage III BRAF-Mutated Melanoma
Georgina V Long, Axel Hauschild, Mario Santinami, et al.
Page
of 71